A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Transplantation

• Publication date

  1997-01-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00007890-199701150-00007PMID 9000657
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pentoxifylline does not prevent the cytokine-induced first dose reaction following OKT3--a randomized, double-blind placebo-controlled study.

  1996cited by this paper
• A DOUBLE‐BLIND, PLACEBO‐CONTROLLED STUDY OF MONOCLONAL ANTI‐INTERLEUKIN-2 RECEPTOR ANTIBODY (BT563) ADMINISTRATION TO PREVENT ACUTE REJECTION AFTER KIDNEY TRANSPLANTATION

  1995cited by this paper
• Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation.

  1995cited by this paper
• Determination of humanized anti-Tac in human serum by a sandwich enzyme linked immunosorbent assay.

  1995cited by this paper
• Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor.

  1994cited by this paper
• The IL-2 receptor complex: its structure, function, and target genes.

  1993cited by this paper
• Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival.

  1991cited by this paper
• A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation.

  1991cited by this paper
• Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys.

  1991cited by this paper
• Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders.

  1990cited by this paper
• Pharmacokinetics of a Mouse/Human Chimeric Monoclonal Antibody (C-17-1 A) in Metastatic Adenocarcinoma Patients

  1990cited by this paper
• Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts.

  1990cited by this paper
• A humanized antibody that binds to the interleukin 2 receptor.

  1989cited by this paper
• Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.

  1989cited by this paper
• Prolongation of primate renal allograft survival by anti-Tac, an anti-human IL-2 receptor monoclonal antibody.

  1989cited by this paper
• Interleukin 2 receptor-targeted therapy--rationale and applications in organ transplantation.

  1988cited by this paper
• Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H.

  1988cited by this paper
• Interleukin-2: inception, impact, and implications.

  1988cited by this paper
• Administration of an anti-interleukin 2 receptor monoclonal antibody prolongs cardiac allograft survival in mice

  1985cited by this paper
• Blockade of the interleukin-2 receptor by anti-Tac antibody: inhibition of human lymphocyte activation.

  1983cited by this paper
• A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor; partial characterization of the receptor

  1982cited by this paper
• A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. II. Expression of Tac antigen on activated cytotoxic killer T cells, suppressor cells, and on one of two types of helper T cells.

  1981cited by this paper
• Letter: Australia antigen in urine.

  1973cited by this paper

• Antilymphocyte Globulin, Monoclonal Antibodies, and Fusion Proteins

  2020cites this paper
• Design, creation and in vitro testing of a reduced immunogenicity humanized anti-CD25 monoclonal antibody that retains functional activity.

  2019cites this paper
• Pharmacokinetics-Based Dosing Strategies for Therapeutic Proteins in Inflammatory Bowel Disease

  2019cites this paper
• Monoclonal Antibodies in Solid Organ Transplantation

  2019cites this paper
• Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013

  2016cites this paper
• Drug Development of Therapeutic Monoclonal Antibodies

  2016cites this paper
• Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers: Integrated Analysis of Intravenous and Subcutaneous, Single- and Multiple-Dose Administration

  2014influential citation
• Changes in peripheral blood Th1 and Th2 cells in rat liver transplantation under different immune statuses.

  2013cites this paper
• Induction Therapy in Renal Transplantation

  2012cites this paper
• The Anti‐Interleukin 2 Receptor Antibodies

  2012cites this paper
• Induction Therapy in Renal Transplant Recipients

  2012cites this paper
• Role of Anti— Interleukin-2 Receptor Antibodies in Kidney Transplantation

  2012cites this paper
• Daclizumab

  2012cites this paper
• 17 Induction Therapy in Renal Transplant Recipients

  2012cites this paper
• Options for Induction Immunosuppression in Liver Transplant Recipients

  2012cites this paper
• Regulatory T cells in kidney transplant recipients: the effect of induction immunosuppression therapy.

  2012cites this paper
• Management of Immune-Mediated Uveitis

  2012cites this paper
• Modern Immunosuppression Regimens in Kidney Transplantation

  2012influential citation
• Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines.

  2012cites this paper
• Daclizumab

  2012cites this paper
• Quantification of circulating regulatory T cells by flow cytometry in kidney transplant patients after basiliximab induction therapy.

  2010cites this paper
• Immunogenicity Assessment of Antibody Therapeutics

  2010cites this paper
• Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies

  2010cites this paper
• Basiliximab Versus Daclizumab Combined With Triple Immunosuppression in Deceased Donor Renal Transplantation: A Prospective, Randomized Study

  2010cites this paper
• Overcoming Chronic Rejection-Can it B?

  2009cites this paper
• Two doses of humanized anti-CD25 antibody in renal transplantation

  2009cites this paper
• Bioanalytical methods for the quantification of therapeutic monoclonal antibodies and their application in clinical pharmacokinetic studies

  2009cites this paper
• Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients

  2008cites this paper
• Comparación de Basiliximab vs. Daclizumab en dosis reducida (2 mg/kg) administrado en dosis única o en dos dosis en receptores de trasplante renal

  2008cites this paper
• Basiliximab vs. limited-dose daclizumab (2 mg/kg) administered in single or two separated doses in kidney transplantation.

  2008cites this paper
• Inflammation after renal transplantation: Role in the development of graft dysfunction and potential therapies

  2008cites this paper
• Chapter 20 – Antibodies and Fusion Proteins

  2008cites this paper
• Immunogenicity screening in protein drug development

  2007cites this paper
• Immunogenicity Issues in the Development of Therapeutic Proteins

  2007cites this paper
• The pharmacokinetics and pharmacodynamics of monoclonal antibodies--mechanistic modeling applied to drug development.

  2007cites this paper
• Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal graft recipients.

  2007cites this paper
• Two-dose daclizumab, tacrolimus, mycophenolate mofetil, and steroid-free regimen in de novo cardiac transplant recipients: early experience.

  2007cites this paper
• The role of basiliximab induction therapy in organ transplantation

  2007cites this paper
• Induction therapy with daclizumab in heart transplantation--how many doses?

  2006cites this paper
• Immunosuppression for pancreas transplantation

  2005cites this paper
• Experience with single-dose daclizumab in the prevention of acute rejection in heart transplantation.

  2005cites this paper
• Induction and Maintenance of Immunosuppression

  2005cites this paper
• Strategien zur Modulation von Protein‐Protein‐Wechselwirkungen mit synthetischen Substanzen

  2005cites this paper
• Daclizumab: humanized monoclonal antibody to the interleukin-2 receptor

  2005cites this paper
• Strategies for targeting protein-protein interactions with synthetic agents.

  2005cites this paper
• Prevention of Early Acute Rejection With Daclizumab and Triple Immunosuppression in Cadaveric Renal Allograft Recipients

  2005cites this paper
• Daclizumab therapy in kidney transplantation-different mechanisms of action in- versus ex-vivo?

  2005cites this paper
• Immunosuppression in pediatric liver and intestinal transplantation: a closer look at the arsenal.

  2005influential citation
• Humanization of Monoclonal Antibodies

  2004cites this paper
• Early experience with two‐dose daclizumab in the prevention of acute rejection in cardiac transplantation

  2004cites this paper
• A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year

  2004cites this paper
• Biomarqueurs et étude pharmacocinétique-pharmacodynamique des immunosuppresseurs.

  2004cites this paper
• Steroid‐Withdrawal at 3 Days After Renal Transplantation with Anti‐IL‐2 Receptor α Therapy: A Prospective, Randomized, Multicenter Study

  2004cites this paper
• The fractional excretion of soluble interleukin-2 receptor-&agr; is an excellent predictor of the interleukin-2 receptor-&agr; status after treatment with daclizumab

  2004cites this paper
• Monitoring of T-cell subsets in patients treated with anti-CD 25 antibody.

  2004cites this paper
• Daclizumab induction in solid organ transplantation

  2004cites this paper
• [Biomarkers and pharmacokinetic-pharmacodynamic studies of immunosuppressive agents].

  2004cites this paper
• Anti-cytokine therapy for the treatment of graft-versus-host disease.

  2004cites this paper
• Evolution of immunosuppression in liver transplantation: contribution of cyclosporine.

  2004cites this paper
• A Truncated-Dose Regimen of Daclizumab for Prevention of Acute Rejection in Kidney Transplant Recipients: A Single-Center Experience

  2004cites this paper
• A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. Ii. Survival, function, and protocol compliance at 1 year

  2004cites this paper
• Transplantation of the Pancreas

  2004cites this paper
• Pharmacologic immunosuppression.

  2004influential citation
• Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti–interleukin-2 receptor monoclonal antibody basiliximab

  2003cites this paper
• The use of daclizumab as induction therapy in combination with tacrolimus and mycophenolate mofetil in recipients with previous transplants

  2003cites this paper
• Efficacy and safety of daclizumab induction for primary kidney transplant recipients in combination with tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression.

  2003cites this paper
• Pharmacokinetic and Pharmacodynamic Studies of One or Two Doses of Daclizumab in Renal Transplantation

  2003cites this paper
• Clinical advances in therapies targeting the interleukin-2 receptor.

  2003cites this paper
• Drugs acting on the immune system

  2003cites this paper
• Anti-Interleukin-2 Receptor Antibodies for the Prevention of Rejection in Pediatric Renal Transplant Patients

  2003cites this paper
• Two-dose daclizumab regimen in simultaneous kidney-pancreas transplant recipients: primary endpoint analysis of a multicenter, randomized study1

  2003cites this paper
• The Rise of Antibodies as Therapeutics

  2002cites this paper
• Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation.

  2002cites this paper
• Anti-CD25 monoclonal antibody coverage allows for calcineurin inhibitor “holiday” in solid organ transplant patients with acute renal dysfunction1

  2002cites this paper
• Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients1

  2002cites this paper
• Down-regulation of IL-2 receptor alpha (CD25) characterizes human gammadelta-T cells rendered resistant to apoptosis after CD2 engagement in the presence of IL-12.

  2002cites this paper
• A multicenter, open‐label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney–pancreas transplant recipients: interim analysis

  2002cites this paper
• Bolus anti-thymocyte globulin induction in renal transplant recipients: a comparison with conventional ATG or anti-interleukin-2 receptor antibody induction.

  2002cites this paper
• Effect of Anti‐IL‐2Rα Antibody on IL‐2‐induced Jak/STAT Signaling

  2002cites this paper
• Inhibition of the IL-15 pathway in anti-CD25 mAb treated renal allograft recipients.

  2002cites this paper
• A multicenter, open-label, comparative trial of two daclizumab dosing strategies versus no antibody induction in simultaneous kidney-pancreas transplantation: 6-month interim analysis.

  2002cites this paper
• Daclizumabof its Use in the Management of Organ Transplantation

  2001cites this paper
• Prophylactic and therapeutic effects of a humanized monoclonal antibody against the IL‐2 receptor (DACLIZUMAB) on collagen‐induced arthritis (CIA) in rhesus monkeys

  2001cites this paper
• Initial clinical experience with interleukin-2 receptor antagonist induction in combination with tacrolimus, mycophenolate mofetil and steroids in simultaneous kidney-pancreas transplantation

  2001cites this paper
• Bispecific human IgG by design.

  2001cites this paper
• Cyclosporine-Associated Thrombotic Microangiopathy during Daclizumab Induction: A Suggested Therapeutic Approach

  2001cites this paper
• Daclizumab induction for primary kidney transplant recipients using tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression.

  2001cites this paper
• Induction immunosuppression with interleukin-2 receptor antibodies (basiliximab and daclizumab) in renal transplant recipients.

  2001cites this paper
• Multicenter survey of daclizumab induction in simultaneous kidney-pancreas transplant recipients.

  2001cites this paper
• A multicenter trial of two daclizumab dosing strategies versus no antibody induction in simultaneous kidney-pancreas transplantation: interim analysis.

  2001cites this paper
• BASILIXIMAB VERSUS ANTITHYMOCYTE GLOBULIN FOR PREVENTION OF ACUTE RENAL ALLOGRAFT REJECTION1,2

  2001cites this paper
• MULTICENTER TRIAL EXPLORING CALCINEURIN INHIBITORS AVOIDANCE IN RENAL TRANSPLANTATION

  2001cites this paper
• The IL2 pathway in clinical immunosuppression.

  2001cites this paper
• Anti-interleukin-2 receptor antibodies: basiliximab and daclizumab.

  2001cites this paper
• [New induction immunosuppression treatments in kidney transplantation].

  2001cites this paper
• Two doses of daclizumab are sufficient for prolonged interleukin-2Ralpha chain blockade.

  2001cites this paper
• Current immunosuppressant regimens: considerations for critical care

  2001cites this paper
• Limited benefits of induction with monoclonal antibody to interleukin-2 receptor in combination with tacrolimus, mycophenolate mofetil, and steroids in simultaneous kidney-pancreas transplantation.

  2001cites this paper
• Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function

  2001cites this paper
• Use of basiliximab and daclizumab in kidney transplantation.

  2001cites this paper